Sinemet 10 mg/100 mg tablets Ireland - English - HPRA (Health Products Regulatory Authority)

sinemet 10 mg/100 mg tablets

organon pharma (ireland) limited - carbidopa; levodopa - tablet - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Sinemet 12.5 mg/50 mg tablets Ireland - English - HPRA (Health Products Regulatory Authority)

sinemet 12.5 mg/50 mg tablets

organon pharma (ireland) limited - carbidopa; levodopa - tablet - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Sinemet 25 mg/250 mg tablets Ireland - English - HPRA (Health Products Regulatory Authority)

sinemet 25 mg/250 mg tablets

organon pharma (ireland) limited - levodopa; carbidopa - tablet - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Sinemet Plus 25 mg/100 mg tablets Ireland - English - HPRA (Health Products Regulatory Authority)

sinemet plus 25 mg/100 mg tablets

organon pharma (ireland) limited - levodopa; carbidopa - tablet - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Half Sinemet CR 25mg/100mg Prolonged-Release Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

half sinemet cr 25mg/100mg prolonged-release tablets

merck sharp & dohme ireland (human health) limited - carbidopa; levodopa - prolonged-release tablet - 25 mg/100 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Sinemet CR 50mg/200 mg Prolonged-release Tablets Ireland - English - HPRA (Health Products Regulatory Authority)

sinemet cr 50mg/200 mg prolonged-release tablets

merck sharp & dohme ireland (human health) limited - levodopa; carbidopa - prolonged-release tablet - 50 mg/ 200 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz) European Union - English - EMA (European Medicines Agency)

corbilta (previously levodopa/carbidopa/entacapone sandoz)

orion corporation - levodopa, carbidopa, entacapone - parkinson disease - anti-parkinson drugs - corbilta is indicated for the treatment of adult patients with parkinson’s disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Madopar 50 mg/12.5 mg dispersible tablets Ireland - English - HPRA (Health Products Regulatory Authority)

madopar 50 mg/12.5 mg dispersible tablets

roche products (ireland) ltd - levodopa; benserazide - dispersible tablet - 50 mg/12.5 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

Madopar 100 mg/25 mg dispersible tablets Ireland - English - HPRA (Health Products Regulatory Authority)

madopar 100 mg/25 mg dispersible tablets

roche products (ireland) ltd - levodopa; benserazide - dispersible tablet - 100 mg/25 milligram(s) - dopa and dopa derivatives; levodopa and decarboxylase inhibitor

COMTAN entacapone 200mg tablet bottle Australia - English - Department of Health (Therapeutic Goods Administration)

comtan entacapone 200mg tablet bottle

sandoz pty ltd - entacapone, quantity: 200 mg - tablet, film coated - excipient ingredients: sucrose; mannitol; glycerol; iron oxide yellow; hypromellose; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; polysorbate 80; iron oxide red; hydrogenated vegetable oil; titanium dioxide - comtan is indicated in the management of parkinson's disease as an adjunct to levodopa/dopa decarboxylase inhibitor therapy in patients who are experiencing motor fluctuations (see clinical trials).